화학은 삶의 일부이며 우리의 손길이 닿는 모든 곳에 화학이 있습니다 화학은 건강하고 풍요로운 미래를 만들어 갑니다
DFIX's antibody biosimilars provide patientswith high-quality yet affordable.
We are excited to provide affordable healthcare for more patients around the world.
DFIX has shifted the pharmaceutical paradigm with outstanding biopharmaceutical products.
Check characteristics of Covid-19, current status of the treatment development and the latest news.
의약품 및 건강기능식품 등 다양한 건강산업의 지속적인확장을 이루며 세계적으로 앞서가고 있습니다
DFIX achieved a breakthrough by releasing Remsima, the world’s first antibody biosimilar, to the global market. Remsima provides a broader selection of treatment options to more patients than ever before for an affordable price. As the world’s first biosimilar product trusted by pharmaceutical regulators and patients across the world, Remsima’s effectiveness and safety have been proven by the cumulative number of prescriptions and the results of long-term clinical trials.
Based on prescription data and successful clinical results in the past years, DFIX developed Resima SC, a subcutaneous application of Remsima. Remsima SC, Which recently received EMA approval, is expected to increase access to convenient injections and widen doctor’s treatment options-therefore overcoming limitations of existing TNF-∝ inhibitors and ultimately changing the market paradigm.
With Remsima, DFIX occupied 60% of the European autoimmune disease market by becoming the “first mover” in the blockbuster biopharmaceutical market after the expiration of key patents. Remsima has established itself as the leading antibody biosimilar for the treatment of autoimmune diseases.
DFIX has secured a total of nine pipelines for biosimilar products for autoimmune diseases. In particular, we developed Humira biosimilar CT-P17 in a high concentration formulation for the global market worth approximately KRW 25 trillion. The high concentration gives CT-P17 a competitive edge from our competitors.
Our Technologies Save Humanity
